The global biomarker discovery outsourcing services market is valued at approximately USD 12.17 billion in 2023 and is projected to grow with a healthy CAGR of 19.4% over the forecast period 2024-2032. Biomarkers play an essential role in disease diagnosis, prognosis, and therapeutic monitoring, fueling their increasing demand across pharmaceutical and biotechnology industries. The market is experiencing significant growth due to technological advancements in omics technologies (genomics, proteomics, metabolomics), artificial intelligence (AI), and machine learning (ML)-driven biomarker identification. Moreover, the growing adoption of personalized medicine, the rising prevalence of chronic diseases, and the need for high-throughput biomarker discovery solutions are further fueling the outsourcing demand.
The pharmaceutical and biotech industries are increasingly outsourcing biomarker research to contract research organizations (CROs) due to cost efficiency, faster drug development timelines, and access to specialized expertise. AI-powered predictive biomarker discovery, multi-omics integration, and growing strategic collaborations between pharma companies and CROs are reshaping the industry landscape. Furthermore, government initiatives and regulatory agency support for biomarker-based clinical trials, particularly from the U.S. FDA, EMA, and ICH, are driving investment in biomarker validation and accelerating market expansion.
The expansion of R&D investments in biopharmaceuticals is another significant factor propelling market growth. With increasing drug development complexities and the shift toward biologics and cell & gene therapies, pharmaceutical companies are allocating larger budgets to biomarker-driven research. This trend has resulted in a surge in industry-academia partnerships, venture capital funding, and government-backed research programs to facilitate biomarker discovery. In addition, the development of non-invasive liquid biopsy biomarkers and digital pathology solutions is enhancing the efficiency of biomarker-based diagnostics. The integration of AI-driven predictive analytics, real-world data, and automation in biomarker discovery further enhances the role of outsourcing in optimizing biopharmaceutical R&D pipelines and improving drug success rates.
As cost efficiency and regulatory compliance become key priorities, outsourcing to specialized CROs and contract development and manufacturing organizations (CDMOs) has emerged as a strategic approach in the biomarker discovery space. These service providers offer end-to-end biomarker discovery solutions, including early-stage biomarker validation, preclinical and clinical validation, and regulatory compliance support, thereby accelerating time-to-market. The market is also witnessing increasing acquisitions, partnerships, and geographic expansions by CROs to meet the rising demand for biomarker discovery services. Additionally, automation in biomarker analysis, cloud-based bioinformatics, and decentralized clinical trials are playing a vital role in shaping future market dynamics.
Major Market Players Included in this Report are:
• LabCorp
• Charles River Laboratories International, Inc.
• Eurofins Scientific
• Celerion
• ICON plc
• Parexel International (MA) Corporation
• Proteome Sciences
• GHO Capital
• Thermo Fisher Scientific Inc.
• Evotec
• Medpace
• BioAgilytix Labs
• Covance Inc.
• WuXi AppTec
• PPD Inc.
The Detailed Segments and Sub-Segment of the Market are Explained Below:
By Biomarker Type:
• Predictive Biomarkers
• Prognostic Biomarkers
• Safety Biomarkers
• Surrogate Endpoints
By Therapeutic Area:
• Oncology
• Neurology
• Cardiology
• Autoimmune Diseases
• Other Therapeutic Areas
By Discovery Phase:
• Biomarker Identification
• Biomarker Validation
• Biomarker Profiling
• Biomarker Panel Development
• Biomarker Selection
By End Use:
• Pharmaceutical Companies
• Biotechnology Companies
• Other End Uses
By Region:
North America:
• U.S.
• Canada
• Mexico
Europe:
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Denmark
• Norway
Asia Pacific:
• Japan
• China
• India
• Australia
• South Korea
• Thailand
Latin America:
• Brazil
• Argentina
Middle East & Africa:
• South Africa
• Saudi Arabia
• UAE
• Kuwait
Years Considered for the Study are as follows:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenue & regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level insights.
• Competitive landscape with information on major industry players.
• Analysis of key business strategies and recommendations on future market approaches.
• Supply and demand analysis of the market
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
- Chapter 1. Global Biomarker Discovery Outsourcing Services Market Executive Summary
- 1.1. Global Biomarker Discovery Outsourcing Services Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Biomarker Type
- 1.3.2. By Therapeutic Area
- 1.3.3. By Discovery Phase
- 1.3.4. By End Use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
- Chapter 2. Global Biomarker Discovery Outsourcing Services Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer’s Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
- Chapter 3. Global Biomarker Discovery Outsourcing Services Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Growing Demand for Personalized Medicine & Biomarker-Based Drug Discovery
- 3.1.2. Increasing Adoption of AI & ML in Biomarker Identification
- 3.1.3. Expansion of Contract Research Organizations (CROs) in Biomarker Discovery Services
- 3.2. Market Challenges
- 3.2.1. Stringent Regulatory Frameworks for Biomarker Validation
- 3.2.2. High Cost of Biomarker Discovery and Data Analysis
- 3.3. Market Opportunities
- 3.3.1. Expansion of Multi-Omics and Big Data Analytics in Biomarker Research
- 3.3.2. Rising Collaborations Between Pharma Companies and CROs
- Chapter 4. Global Biomarker Discovery Outsourcing Services Market Industry Analysis
- 4.1. Porter’s 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter’s 5 Force Model
- 4.1.7. Porter’s 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
- Chapter 5. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Biomarker Type (2022-2032)
- 5.1. Segment Dashboard
- 5.2. Revenue Trend Analysis (USD Million/Billion)
- 5.3. Predictive Biomarkers
- 5.4. Prognostic Biomarkers
- 5.5. Safety Biomarkers
- 5.6. Surrogate Endpoints
- Chapter 6. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Therapeutic Area (2022-2032)
- 6.1. Segment Dashboard
- 6.2. Revenue Trend Analysis (USD Million/Billion)
- 6.3. Oncology
- 6.4. Neurology
- 6.5. Cardiology
- 6.6. Autoimmune Diseases
- 6.7. Other Therapeutic Areas
- Chapter 7. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Discovery Phase (2022-2032)
- 7.1. Segment Dashboard
- 7.2. Revenue Trend Analysis (USD Million/Billion)
- 7.3. Biomarker Identification
- 7.4. Biomarker Validation
- 7.5. Biomarker Profiling
- 7.6. Biomarker Panel Development
- 7.7. Biomarker Selection
- Chapter 8. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by End Use (2022-2032)
- 8.1. Segment Dashboard
- 8.2. Revenue Trend Analysis (USD Million/Billion)
- 8.3. Pharmaceutical Companies
- 8.4. Biotechnology Companies
- 8.5. Other End Use
- Chapter 9. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Region (2022-2032)
- 9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Mexico
- 9.2. Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Sweden
- 9.2.7. Denmark
- 9.2.8. Norway
- 9.3. Asia Pacific
- 9.3.1. Japan
- 9.3.2. China
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Thailand
- 9.4. Latin America
- 9.4.1. Brazil
- 9.4.2. Argentina
- 9.5. Middle East & Africa
- 9.5.1. South Africa
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Kuwait
- Chapter 10. Competitive Intelligence
- 10.1. Key Company SWOT Analysis
- 10.1.1. LabCorp
- 10.1.2. Charles River Laboratories
- 10.1.3. Thermo Fisher Scientific
- 10.2. Top Market Strategies
- 10.3. Company Profiles
- 10.3.1. LabCorp
- 10.3.2. Charles River Laboratories
- 10.3.3. Eurofins Scientific
- 10.3.4. Celerion
- 10.3.5. ICON plc
- 10.3.6. Parexel International (MA) Corporation
- 10.3.7. Proteome Sciences
- 10.3.8. GHO Capital
- 10.3.9. Thermo Fisher Scientific Inc.
- 10.3.10. Evotec
- Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes
- List of Tables
- 1. Global Biomarker Discovery Outsourcing Services Market Estimates & Forecasts by Region (2022-2032)
- 2. Global Biomarker Discovery Outsourcing Services Market by Biomarker Type (2022-2032)
- 3. Global Biomarker Discovery Outsourcing Services Market by Therapeutic Area (2022-2032)
- 4. Global Biomarker Discovery Outsourcing Services Market by Discovery Phase (2022-2032)
- 5. Global Biomarker Discovery Outsourcing Services Market by End Use (2022-2032)
- (This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.)
- List of Figures
- 1. Global Biomarker Discovery Outsourcing Services Market, Research Methodology
- 2. Market Estimation Techniques
- 3. Market Size Estimates & Forecast (2022-2032)
- 4. Market Share by Biomarker Type (2023 & 2032)
- 5. Market Share by Therapeutic Area (2023 & 2032)
- 6. Market Share by Discovery Phase (2023 & 2032)
- 7. Competitive Landscape Analysis
- (This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook